Key Takeaways
- • Salt Capital and Proparco have jointly acquired The Namibian Oncology Centre (NOC), a specialist cancer care provider founded by local Namibian clinicians, healthcare professionals, and businesspeople.
- • The acquisition reflects both investors' commitment to expanding access to oncology care and cancer diagnosis in Sub-Saharan Africa, aligning with Proparco's 2023-2027 development strategy focused on reducing healthcare inequalities in developing markets.
- • Jan Bosch, managing partner of Salt Capital, emphasized the investment's focus on supporting NOC's mission, strengthening healthcare standards, and advancing cancer awareness across Namibia.
- • The transaction represents a significant institutional capital deployment into African healthcare infrastructure, targeting underserved cancer care markets where access remains constrained.
Summary
Salt Capital and Proparco, the French development finance institution, have completed an acquisition of The Namibian Oncology Centre, a specialist cancer care provider operating in Namibia. The centre was established by a consortium of local Namibian clinicians, healthcare professionals, and business operators, positioning it as a critical infrastructure asset within the country's healthcare ecosystem.
The partnership between Salt Capital and Proparco reflects a coordinated institutional approach to healthcare infrastructure investment in Sub-Saharan Africa. Jan Bosch, managing partner of Salt Capital, characterized the acquisition as an honour to have been selected by the founders as long-term partners, emphasizing the firm's commitment to supporting NOC's core mission while strengthening healthcare standards and advancing cancer awareness and access to care across Namibia. The investment is positioned with focus on operational sustainability and service quality expansion.
Johann Choux, Proparco's regional director for Southern Africa and the Indian Ocean, framed the acquisition within the institution's broader 2023-2027strategic framework, which prioritizes partnering with local market participants to deliver measurable development impact. Choux specifically noted the transaction's alignment with Proparco's objective of reducing inequalities in access to essential services while supporting the sustainability and quality of care infrastructure in developing countries.
The Namibian Oncology Centre has historically played a foundational role in expanding access to cancer diagnosis, treatment, and comprehensive care services within Namibia. The acquisition by institutional capital partners suggests both investor confidence in the centre's operational model and recognition of the significant healthcare access gap in oncology services across the Southern African region. The investment underscores growing institutional appetite for healthcare infrastructure assets in emerging markets where specialized care providers remain limited.
The partnership between Salt Capital and Proparco reflects a coordinated institutional approach to healthcare infrastructure investment in Sub-Saharan Africa. Jan Bosch, managing partner of Salt Capital, characterized the acquisition as an honour to have been selected by the founders as long-term partners, emphasizing the firm's commitment to supporting NOC's core mission while strengthening healthcare standards and advancing cancer awareness and access to care across Namibia. The investment is positioned with focus on operational sustainability and service quality expansion.
Johann Choux, Proparco's regional director for Southern Africa and the Indian Ocean, framed the acquisition within the institution's broader 2023-2027strategic framework, which prioritizes partnering with local market participants to deliver measurable development impact. Choux specifically noted the transaction's alignment with Proparco's objective of reducing inequalities in access to essential services while supporting the sustainability and quality of care infrastructure in developing countries.
The Namibian Oncology Centre has historically played a foundational role in expanding access to cancer diagnosis, treatment, and comprehensive care services within Namibia. The acquisition by institutional capital partners suggests both investor confidence in the centre's operational model and recognition of the significant healthcare access gap in oncology services across the Southern African region. The investment underscores growing institutional appetite for healthcare infrastructure assets in emerging markets where specialized care providers remain limited.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.